Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01453387 · ClinicalTrials.gov registry record · Phase 1
MSC2015103B in Solid Tumors
A Phase 1 study, sponsored by EMD Serono.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01453387 is a Phase 1 study that was terminated before completion, run by EMD Serono. The registered enrollment target is 28 participants.
The verdict
NCT01453387, a Phase 1 study, was terminated before completion, sponsored by EMD Serono.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The main purpose of this study is to test the experimental drug, MSC2015103B at different dose levels and on different treatment schedules, to see whether it is safe and can be tolerated when given to subjects once a day one day per week over a 21-day period or once a day three times per week over a 21-day period. The investigators would also like to find out how MSC2015103B is broken down by the body. Additional purposes of the trial are to assess side effects of MSC2015103B and to find out whether MSC2015103B has anti-cancer effects. In addition, the investigators would like to explore pharmacokinetics.
Interventions
- DRUG MSC2015103B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01453387
The ClinicalTrials.gov registry entry for NCT01453387 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MSC2015103B is the first listed.
NCT01453387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01453387 about?
NCT01453387 is a clinical study titled "MSC2015103B in Solid Tumors". The main purpose of this study is to test the experimental drug, MSC2015103B at different dose levels and on different treatment schedules, to see whether it is safe and can be tolerated when given to subjects once a day one day per week over a 21-day period or once a day three times per week over a...
What is the current status of trial NCT01453387?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-09. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01453387?
The interventions under investigation include: MSC2015103B (DRUG).
Who is sponsoring clinical trial NCT01453387?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.